Our company is focused on developing minimally invasive therapeutic technologies. We offer our customers products of high quality, through research and careful selection of components and raw materials, entrusting only certified suppliers. We are committed to providing quality medical devices that are used to save or enhance the lives of the patients we serve.
Naama Sara Reich
naama.re@synergo-medical.com
6 Odem st
+97239244830
http://www.synergo-medical.com
Company's Solutions
Our lead product, Synergo® RITE, delivers local bladder microwave (RF) and tissue hyperthermia with simultaneous chemotherapy instillation for the treatment of intermediate and high-risk non-muscle invasive bladder cancer.
Used on an outpatient basis, Synergo® RITE potentiates chemotherapy routinely used by urologists, resulting in a considerably higher efficacy and favorable clinical outcomes. With over 50 publications, including randomized controlled trials and EAU guideline recommendation, Synergo® RITE has become a well-established evidence-based treatment for clinicians to offer their patients with bladder cancer.
NICE MTEP: "Models using Synergo resulted in a reduction in radical cystectomies, an increase in total life years and an increase in quality-adjusted life years (QALYs)".
Prominent Case Study
Bladder cancer disease is a rare phenomenon in children, with an incidence rate of 0.1-0.4% during the first two decades of their lives. Thousands of patients have been treated so far with Synergo technology but we are only aware of 1 child.
Shaare Zedek Medical Center (Jerusalem) recently summarized their experience and treatment outcomes in nine children.
A single case of high-grade cancer disease was diagnosed in a 14-year-old girl, a kidney transplant recipient.
Doctors gave her six Synergo treatments and she is free of cancer to date (>4 years).